Recent Projects

Health Economics Outcomes Research (HEOR):

End-Stage Renal Disease

  • Real-World Evidence (RWE) of Dosing Differences between competing anemia treatments (2019-2020)

  • Real-World Evidence of Patient Outcomes for Mineral and Bone Disorders based on timing of initiation of calcimimetic treatment (2019-2021)

  • Analysis of changes in Dialysis Center Efficiency (2016-2019)

  • Reasons for Blood Transfusion in U.S. Dialysis Patients (2015-2017)

  • Literature reviews on dose conversions between anemia drugs (2016-2018)

Supportive Care in Cancer Treatment

  • Time and Travel Burden on patients and caregivers related to cancer therapy (2015-2017)

  • Effects of Patient Travel Time on Optimal Cancer therapy and Outcomes (2015-2018)

  • Geographic disparities in supportive cancer care (2015-2017)

Multiple Sclerosis

  •  Outcomes of Switching Stable MS Patients’ Interferon therapies (2017-18)


  • Travel burden related to hyperlipidemia treatment (2015-2016)

Medical Devices

  • Evidence Review in support of reimbursement submission for an an acellular biologic matrix for hernia and breast repair (2015)

Provider Operations and Financial Analysis, Payment Systems Analysis:

  • Custom Dialysis Industry Benchmarking Reports (2012-present)

  • Payment Calculator for ESRD PPS Payments from Medicare for dialysis (2016-present)

  • Cost Evaluation of various Anemia Management Protocols (2014-2018)

  • Strategy planning and consulting related to biosimilar competition in Anemia Management drugs (2016-2018)

  • Feasibility study and prototype for a Standardized Mortality Rate tracking system (2014)

  • Development and ongoing reporting from a Five-Year Cost and Outcomes Database for U.S. Dialysis Facilities (2013-present)

  •  Custom Cost and Quality Benchmarking Studies and Reports (2013-present)

  •  The Financial Effects of Case Mix Coding Variance on ESRD PPS Payments (2013-2015)

  •  Geographic Feasibility Study for Participation in ESRD Seamless Care Organizations (2013)

Health Payment Policy and Reimbursement Analysis:

  • Financial Impact Analysis of proposed staffing requirements for California Dialysis Clinics (2017)

  • Financial Impact Studies of the ESRD PPS Payment Re-basing and Annual Updates (2013-present)

  • Research reimbursement pathways in the US for top-tier biologics for treatment of rheumatoid arthritis (2015)

  • Analysis of dialysis facilities with financial losses 2019-2021 (2022)

  • Analysis of dialysis facility closures 2020-2022 and impacts to patient access to care (2023)

  • Analysis of impacts to reimbursement of changes to cost weights and labor-related share in the ESRD PPS payment formula (2023)

Customer-Facing Sales, Value and Access Tools for Biologics (FDAMA-114, etc)

  • Budget Impact Models for Switching Anemia Management Drugs (2013-2020)

  • ESA Purchase Contract Estimator Tools (2016-2020)

  • ESA Dosage and Hemoglobin Trend Reporting Tools for Dialysis Organizations (2013-present)

  • Interactive Contract Performance Tracking Tools (Purchase Volume Tracking) (2017-present)

  • Stocking and Ordering Tool for Calcimimetics Supply (2017)

  • Sales Tracking and Reporting Tools for Calcimimetics and asthma treatments (2017-present)

  • ESA Dose and Cost Comparisons between competing products based on Real World Evidence (2019-2020)